872367-64-1

Upstream product

• 315-14-0 1,3,5-trifluoro-2-nitrobenzene 
• 74-89-5 methylamine 

Downstream Products

• 1329166-95-1 2-chloro-3,5-difluoro-N-methyl-6-nitroaniline 
• 1581683-90-0 2-(3-((4-(3-(aminomethyl)azetidin-1-yl)-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-yl)oxy)-5-cyanophenoxy)acetic acid trifluoroacetate 
• 1581683-88-6 2-(3-((8-((tert-butoxycarbonyl)(methyl)amino)-4-(3-(((tert-butoxycarbonyl)amino)methyl)azetidin-1-yl)-6-fluoro-9H-pyrimido[4,5-b]indol-2-yl)oxy)-5-cyanophenoxy)acetic acid 
• 1581683-87-5 ethyl 2-(3-((8-((tert-butoxycarbonyl)(methyl)amino)-4-(3-(((tert-butoxycarbonyl)amino)methyl)azetidin-1-yl)-6-fluoro-9H-pyrimido[4,5-b]indol-2-yl)oxy)-5-cyanophenoxy)acetate 
• 1581683-86-4 diethyl 2,2'-((((8-((tert-butoxycarbonyl)(methyl)amino)-6-fluoro-9H-pyrimido[4,5-b]indole-2,4-diyl)bis(oxy))bis(3-cyano-5,1-phenylene))bis(oxy))diacetate 
• 1581683-77-3 tert-butyl (4-(benzylsulfonyl)-6-fluoro-2-((2-(methylsulfonyl)pyrimidin-5-yl)oxy)-9H-pyrimido[4,5-b]indol-8-yl)(methyl)carbamate 
• 1581683-76-2 tert-butyl (4-(benzylthio)-6-fluoro-2-((2-(methylthio)pyrimidin-5-yl)oxy)-9H-pyrimido[4,5-b]indol-8-yl)(methyl)carbamate 
• 1400808-33-4 tert-butyl N-[2,4-bis(benzylsulfonyl)-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methylcarbamate 
• 1400808-29-8 C₁₅H₁₅FN₄O₄ 
• 1400808-17-4 C₂₀H₂₅FN₄O₅S 
• 1400808-15-2 C₁₇H₂₀FN₃O₆ 
• 1400808-32-3 tert-butyl 2,4-bis(benzylthio)-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl(methyl)carbamate 
• 1400808-30-1 tert-butyl 2-amino-3-cyano-5-fluoro-1H-indol-7-yl(methyl)carbamate 
• 1400808-14-1 tert-butyl 3,5-difluoro-2-nitrophenyl(methyl)carbamate 

Relevant academic research and scientific papers

9 MEMBERED CONDENSED-RING DERIVATIVE

PROBLEM TO BE SOLVED: To provide a novel compound having ACC2 inhibitory activity. SOLUTION: The present invention provides a compound having a substituted or unsubstituted condensed aromatic heterocyclic group represented by formula I or a pharmaceutically acceptable salt thereof, where R1 is represented by the following formula (ring B is 5 membered ring and ring C is 6 membered ring). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

NOVEL ALKYLENE DERIVATIVE

The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is -O-(CR6R7)m- etc., -L2- is -O-(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc..

TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

TRICYCLIC GYRASE INHIBITORS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

MACROCYCLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.